Administration of Bifidobacterium breve Decreases the Production of TNF-α in Children with Celiac Disease

Digestive Diseases and Sciences

Volumn 60, Issue 11, 2015, Pages 3386-3392

  Klemenak, Martina ^a   Dolinšek, Jernej ^a   Langerholc, Tomaž ^b   Di Gioia, Diana ^c   Mičetić Turk, Dušanka ^b  

^a UNIVERSITY MEDICAL CENTRE MARIBOR   (Slovenia)

^b UNIVERSITY OF MARIBOR   (Slovenia)

^c UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

Bifidobacterium breve; Celiac disease; Children; Cytokines; TNF

Indexed keywords

BIFIDOBACTERIUM BREVE EXTRACT; INTERLEUKIN 10; PROBIOTIC AGENT; TUMOR NECROSIS FACTOR ALPHA; AUTACOID; BIOLOGICAL MARKER; IL10 PROTEIN, HUMAN;

ARTICLE; BACTERIAL STRAIN; BIFIDOBACTERIUM BREVE; CELIAC DISEASE; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DOUBLE BLIND PROCEDURE; FEMALE; FOLLOW UP; GLUTEN FREE DIET; HUMAN; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; ADOLESCENT; AGE; BIFIDOBACTERIUM; BLOOD; DOWN REGULATION; IMMUNOLOGY; MICROBIOLOGY; MULTIMODALITY CANCER THERAPY; PHYSIOLOGY; PRESCHOOL CHILD; SLOVENIA; SMALL INTESTINE; TIME; TREATMENT OUTCOME;

ADOLESCENT; AGE FACTORS; BIFIDOBACTERIUM; BIOMARKERS; CELIAC DISEASE; CHILD; CHILD, PRESCHOOL; COMBINED MODALITY THERAPY; DIET, GLUTEN-FREE; DOUBLE-BLIND METHOD; DOWN-REGULATION; FEMALE; HUMANS; INFLAMMATION MEDIATORS; INTERLEUKIN-10; INTESTINE, SMALL; MALE; PROBIOTICS; SLOVENIA; TIME FACTORS; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84945436179     PISSN: 01632116     EISSN: 15732568     Source Type: Journal    
DOI: 10.1007/s10620-015-3769-7     Document Type: Article

References (33)

1. Husby S, Koletzko S, Korponay-Szabó IR, et al. European society for pediatric gastroenterology, hepatology, and nutrition guidelines for the diagnosis of coeliac disease. J Pediatr Gastroenterol Nutr. 2012;54:136–160.
2. McAllister CS, Kagnoff MF. The immunopathogenesis of celiac disease reveals possible therapies beyond the gluten-free diet. Semin Immunopathol. 2012;34:581–600.
3. Salvati VM, Mazzarella G, Gianfrani C, et al. Recombinant human interleukin 10 suppresses gliadin dependent T cell activation in ex vivo cultured coeliac intestinal mucosa. Gut. 2005;54:46–53.
4. Manavalan JS, Hernandez L, Shah JG, et al. Serum cytokine elevations in celiac disease: association with disease presentation. Hum Immunol. 2010;71:50–57.
5. Cataldo F, Lio D, Marino V, et al. Plasma cytokine profiles in patients with celiac disease and selective IgA deficiency. Pediatr Allergy Immunol. 2003;14:320–324.
6. Pallav K, Kabbani T, Tariq S, Vanga R, Kelly CP, Leffler DA. Clinical utility of celiac disease-associated HLA testing. Dig Dis Sci. 2014;59:2199–2206.
7. Collado MC, Donat E, Ribes-Koninckx C, Calabuig M, Sanz Y. Specific duodenal and faecal bacterial groups associated with paediatric coeliac disease. J Clin Pathol. 2009;62:264–269.
8. Sánchez E, Donat E, Ribes-Koninckx C, Fernández-Murga ML, Sanz Y. Duodenal-mucosal bacteria associated with celiac disease in children. Appl Environ Microbiol. 2013;79:5472–5479.
9. Di Cagno R, De Angelis M, De Pasquale I, et al. Duodenal and faecal microbiota of celiac children: molecular, phenotype and metabolome characterization. BMC Microbiol. 2011;11:219.
10. Tursi A, Elisei W, Giorgetti GM, Brandimarte G, Aiello F. Complications in celiac disease under gluten-free diet. Dig Dis Sci. 2009;54:2175–2182.
11. Tuire I, Marja-Leena L, Teea S, et al. Persistent duodenal intraepithelial lymphocytosis despite a long-term strict gluten-free diet in celiac disease. Am J Gastroenterol. 2012;107:1563–1569.
12. Mäki M. Celiac disease treatment: gluten-free diet and beyond. J Pediatr Gastroenterol Nutr. 2014;59:S15–S17.
13. Kverka M, Tlaskalova-Hogenova H. Two faces of microbiota in inflammatory and autoimmune diseases: triggers and drugs. APMIS Acta Pathol Microbiol Immunol Scand. 2013;121:403–421.
14. De Palma G, Cinova J, Stepankova R, Tuckova L, Sanz Y. Pivotal Advance: Bifidobacteria and Gram-negative bacteria differentially influence immune responses in the proinflammatory milieu of celiac disease. J Leukoc Biol. 2010;87:765–778.
15. López P, Gueimonde M, Margolles A, Suárez A. Distinct Bifidobacterium strains drive different immune responses in vitro. Int J Food Microbiol. 2010;138:157–165.
16. He F, Morita H, Ouwehand AC, et al. Stimulation of the secretion of pro-inflammatory cytokines by Bifidobacterium strains. Microbiol Immunol. 2002;46:781–785.
17. Aloisio I, Santini C, Biavati B, et al. Characterization of Bifidobacterium spp. strains for the treatment of enteric disorders in newborns. Appl Microbiol Biotechnol. 2012;96:1561–1576.
18. Mogna L, Del Piano M, Mogna G. Capability of the two microorganisms Bifidobacterium breve B632 and Bifidobacterium breve BR03 to colonize the intestinal microbiota of children. J Clin Gastroenterol. 2014;48:S37–S39.
19. EFSA publication. EFSA BIOHAZ Panel (EFSA Panel on Biological Hazards), 2013. Scientific Opinion on the maintenance of the list of QPS biological agents intentionally added to food and feed (2013 update). Parma, Italy: European Food Safety Authority, 2013. (The EFSA Journal. 2013;11:3449). doi:10.2903/j.efsa.2013.3449. Accessed 10 Mar 2015.
20. Jeon SG, Kayama H, Ueda Y, et al. Probiotic Bifidobacterium breve induces IL-10-producing Tr1 cells in the colon. PLoS Pathog. 2012;8:e1002714.
21. Zheng B, van Bergenhenegouwen J, Overbeek S, et al. Bifidobacterium breve attenuates murine dextran sodium sulfate-induced colitis and increases regulatory T cell responses. PloS One. 2014;9:e95441.
22. Yudoh K, Matsuno H, Nakazawa F, Yonezawa T, Kimura T. Reduced expression of the regulatory CD4+ T cell subset is related to Th1/Th2 balance and disease severity in rheumatoid arthritis. Arthritis Rheum. 2000;43:617–627.
23. Lauret E, Rodrigo L. Celiac disease and autoimmune-associated conditions. BioMed Res Int. 2013;2013:127589.
24. Revised criteria for diagnosis of coeliac disease. Report of working group of European society of paediatric gastroenterology and nutrition. Arch Dis Child. 1990;65:909–911.
25. Sollid LM, Khosla C. Novel therapies for coeliac disease. J Intern Med. 2011;269:604–613.
26. Sullivan KE, Cutilli J, Piliero LM, et al. Measurement of cytokine secretion, intracellular protein expression, and mRNA in resting and stimulated peripheral blood mononuclear cells. Clin Diagn Lab Immunol. 2000;7:920–924.
27. D’Arienzo R, Maurano F, Lavermicocca P, Ricca E, Rossi M. Modulation of the immune response by probiotic strains in a mouse model of gluten sensitivity. Cytokine. 2009;48:254–259.
28. Medina M, De Palma G, Ribes-Koninckx C, Calabuig M, Sanz Y. Bifidobacterium strains suppress in vitro the pro-inflammatory milieu triggered by the large intestinal microbiota of coeliac patients. J Inflamm Lond Engl. 2008;5:19.
29. Laparra JM, Sanz Y. Bifidobacteria inhibit the inflammatory response induced by gliadins in intestinal epithelial cells via modifications of toxic peptide generation during digestion. J Cell Biochem. 2010;109:801–807.
30. Smecuol E, Hwang HJ, Sugai E, et al. Exploratory, randomized, double-blind, placebo-controlled study on the effects of Bifidobacterium infantis natren life start strain super strain in active celiac disease. J Clin Gastroenterol. 2013;47:139–147.
31. Olivares M, Castillejo G, Varea V, Sanz Y. Double-blind, randomised, placebo-controlled intervention trial to evaluate the effects of Bifidobacterium longum CECT 7347 in children with newly diagnosed coeliac disease. Br J Nutr. 2014;112:30–40.
32. Branski D, Fasano A, Troncone R. Latest developments in the pathogenesis and treatment of celiac disease. J Pediatr. 2006;149:295–300.
33. Whorwell PJ, Altringer L, Morel J, et al. Efficacy of an encapsulated probiotic Bifidobacterium infantis 35624 in women with irritable bowel syndrome. Am J Gastroenterol. 2006;101:1581–1590.